Merck & Co. Heads Into A Year Of Portfolio Expansion

The company expects new products like the pneumococcal vaccine V116, the PAH treatment sotatercept and the ADC patritumab deruxtecan will begin contributing to revenue growth in the near term.

branch growing
Merck & Co. could add three new brands to its portfolio this year. • Source: Shutterstock

Merck & Co., Inc.’s portfolio diversification strategy is expected to begin bearing fruit this year, with the company preparing for several new drug and vaccine launches in 2024. Merck expects a new 21-valent pneumococcal vaccine V116, the activin-signaling inhibitor sotatercept for pulmonary arterial hypertension (PAH), and the antibody-drug conjugate patritumab deruxtecan for metastatic EGFR-mutated non-small cell lung cancer to begin contributing to revenue in the second half of the year, if those products are approved as expected.

Sotatercept and patritumab deruxtecan both came from Merck’s business development initiative, largely aimed at diversifying the company away from its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.